Details

Autor(en) / Beteiligte

• Wang, Michael L
• Rule, Simon
• Martin, Peter
• Goy, Andre
• Auer, Rebecca
• Kahl, Brad S
• Jurczak, Wojciech
• Advani, Ranjana H
• Romaguera, Jorge E
• Williams, Michael E
• Barrientos, Jacqueline C
• Chmielowska, Ewa
• Radford, John
• Stilgenbauer, Stephan
• Dreyling, Martin
• Jedrzejczak, Wieslaw Wiktor
• Johnson, Peter
• Spurgeon, Stephen E
• Li, Lei
• Zhang, Liang
• Newberry, Kate
• Ou, Zhishuo
• Cheng, Nancy
• Fang, Bingliang
• McGreivy, Jesse
• Clow, Fong
• Buggy, Joseph J
• Chang, Betty Y
• Beaupre, Darrin M
• Kunkel, Lori A
• Blum, Kristie A

Titel

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Ist Teil von

• The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Mantle-cell lymphoma is often refractory to treatment, especially in response to second-line therapy. Inhibition of the Bruton's tyrosine kinase with ibrutinib produced responses in two thirds of patients in a phase 2 study; 21% of patients had a complete response. Mantle-cell lymphoma is a distinct subtype of non-Hodgkin's lymphoma that has an aggressive clinical course and a poor prognosis. 1 Current frontline combination chemotherapies 2 and intensive chemoimmunotherapy followed by stem-cell transplantation have improved the outcome for patients with this disease. 3 , 4 Although these regimens have high initial response rates, most patients eventually have a relapse and die from mantle-cell lymphoma. More effective agents are needed. Constitutive activation of B-cell receptor signaling appears to be essential for the survival and proliferation of malignant B cells, an observation that has led to the design of inhibitors of B-cell receptor–associated kinases. 3 – 5 Bruton's tyrosine . . .